InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,070.55
(
1.20%
)
US TECH 100
17,095.60
(
2.05%
)
Dow Jones
38,503.69
(
0.69%
)
Brent Oil
87.59
(
0.02%
)
Bitcoin
66,699.58
(
0.44%
)
Post# of 251581
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

AlpineBV_Miller

Send PM Follow Ignore
Followers 56
Posts 1150
Boards Moderated 0
Alias Born 11/12/2005

AlpineBV_Miller

Re: mcbio post# 132638

Friday, 12/09/2011 12:21:00 PM

Friday, December 09, 2011 12:21:00 PM

Post# of 251581
The data is a 3-step process CRO --> data analysis firm --> PYMX. All PYMX got was the four numbers. I'm more peeved at the fact they didn't give unblinded data like they said they would. There is no valid reason to preserve alpha in an exploratory Phase IIa dose-finding trial.

Since they also gave an average for the four arms, it can't be 87-87-87-100.

Unless otherwise indicated, this is the personal viewpoint of David
Miller and not necessarily that of Biotech Stock Research, LLC.
We're on Twitter at BiotechStockRsr

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up